Skip to Content

Eskalith FDA Alerts

The FDA Alerts below may be specifically about Eskalith or relate to a group or class of drugs which include Eskalith.

MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings.

Recent FDA Alerts for Eskalith

Carbolith (lithium carbonate)

The FDA advised consumers about a Canadian recall of Carbolith (lithium carbonate) 150 mg capsules distributed in Canada by Valeant Canada Limited. Although Carbolith is not an FDA-approved product, FDA is investigating several Internet websites advertising Carbolith for sale to U.S. consumers. Carbolith 150 mg capsules are used in the treatment of manic-depressive illness. The company's recent testing led to the conclusion that the product may not deliver adequate amounts of the drug to ensure effective treatment. U.S. consumers who have taken it for the treatment of manic-depressive illness could experience adverse events associated with lowered blood lithium levels.

[December 8, 2004 - Talk Paper - FDA]


More Eskalith Resources